Home›Drug Pipeline› Chemokine network emerges as rational lupus nephritis target as standard therapy fails 30% to 40%
Chemokine network emerges as rational lupus nephritis target as standard therapy fails 30% to 40%Chemokine Networks May Offer New Targets for Lupus Nephritis
Frontiers in MedicinePublished August 24, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider chemokine-targeted therapies as an emerging but not yet clinically ready option for lupus nephritis.
This systematic review examines the role of the chemokine system, including small secreted proteins and G protein-coupled receptors, in the pathogenesis of lupus nephritis (LN) and its potential as a therapeutic target. The review synthesizes preclinical and clinical evidence to describe how chemokines orchestrate pathogenic immune cell infiltration, renal inflammation, and progressive fibrosis, which are key drivers of LN progression.
The authors highlight a significant clinical gap: current standard therapies, which combine glucocorticoids with conventional immunosuppressants, fail to achieve sustained remission in 30% to 40% of patients. These therapies are also associated with adverse events such as infections, osteoporosis, and cardiovascular disease, underscoring the need for more targeted approaches.
The review identifies the chemokine network as a rational therapeutic target, given its central role in LN pathogenesis. However, the authors note several limitations, including a disconnect between preclinical findings and clinical outcomes, the complexity of selecting the right chemokine targets, and safety concerns that need to be addressed.
While the review provides a comprehensive overview of the chemokine network's potential, it does not report pooled effect sizes or specific clinical trial data. The conclusions are based on a synthesis of existing evidence, and the authors emphasize that further research is needed to translate these insights into effective therapies.
For clinicians, this review reinforces the limitations of current LN treatments and highlights an emerging area of therapeutic development. However, given the preclinical-clinical disconnect and unresolved safety issues, chemokine-targeted therapies are not yet ready for clinical use.
How this fits prior evidence
This systematic review extends prior coverage by addressing a mechanistic gap in lupus nephritis treatment. While prior items noted that natural products may modulate gut microbiota for renal protection and that APOL1 genotypes increase ESRD risk, this review focuses on the chemokine network as a direct driver of renal pathology. It confirms the need for novel therapies, as standard care fails in 30% to 40% of patients, and contrasts with the RA finding that tailored DMARD selection did not improve outcomes, suggesting that targeted approaches may be more promising in LN. The review also aligns with the CAR T-cell finding by exploring another targeted strategy for SLE, though at a preclinical stage.
Current standard treatments for lupus nephritis, which include glucocorticoids and immunosuppressants, are not always successful. This review found that about 30% to 40% of patients do not achieve sustained remission with these current therapies. Additionally, these standard medications can lead to side effects like infections, osteoporosis, and cardiovascular disease.
The study looked at the role of chemokines in the progression of the disease. Chemokines are proteins that help direct immune cells into tissues. The review found that these molecules play a key role in causing inflammation in the kidneys and leading to progressive scarring, known as fibrosis.
Because current treatments have limitations, the chemokine network is being looked at as a new target for therapy. However, there are still challenges to overcome. These include a gap between early laboratory findings and clinical results, the complexity of choosing specific targets, and potential safety concerns. More research is needed to determine how these findings can be safely used in medical practice.
What this means for you:
The chemokine network may offer a new way to treat lupus nephritis when standard therapies are not effective.
Common questions
Why are new treatments being looked at for lupus nephritis?
Current standard therapies, such as glucocorticoids and immunosuppressants, fail to achieve sustained remission in 30% to 40% of patients. Because these current treatments can also cause side effects like infections or cardiovascular disease, researchers are looking for new targets like the chemokine network to improve patient outcomes.
What role do chemokines play in lupus nephritis?
Chemokines are part of a system that orchestrates immune cell infiltration and renal inflammation. The review found that these molecules also contribute to progressive fibrosis, which is the scarring of kidney tissue. This makes them a potential target for new medical treatments.
Are there risks associated with targeting the chemokine system?
While the chemokine network is a rational target because current therapies have limitations, there are still hurdles to clear. These include a disconnect between preclinical and clinical results, the complexity of selecting specific targets, and general safety concerns that must be addressed before new treatments can be used.
Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), affecting more than 50% of SLE patients and remaining a leading cause of end-stage renal disease (ESRD) worldwide. Current standard therapies—glucocorticoids combined with conventional immunosuppressants—fail to achieve sustained remission in 30%–40% of patients and are associated with substantial toxicities, including infections, osteoporosis, and cardiovascular disease. The chemokine system, composed of small secreted proteins and their G protein-coupled receptors (GPCRs), plays a central role in LN pathogenesis by orchestrating pathogenic immune cell infiltration, renal inflammation, and progressive fibrosis. This review synthesizes preclinical and clinical evidence establishing the chemokine network as a rational therapeutic target in LN. We first outline the clinical burden of LN and the limitations of existing therapies, followed by a systematic overview of chemokine biology (classification, structural interactions, and leukocyte trafficking functions). Next, we dissect the pathogenic roles of chemokines in LN, focusing on their secretion by resident renal cells, regulation of immune cell infiltration, and association with renal fibrosis. Subsequently, we evaluate therapeutic advances targeting chemokines, including small-molecule antagonists, monoclonal antibodies, and upstream pathway interventions, while discussing translational challenges (e.g., preclinical-clinical disconnect, complexity of target selection, safety concerns). Finally, we highlight emerging technologies, opportunities for personalized medicine, and long-term research priorities to facilitate the development of chemokine-based therapeutic strategies for LN.
